Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome (PWS-GXR)

NCT05657860 PHASE4 COMPLETED

This is a placebo-controlled clinical trial to assess whether Guanfacine Extended Release (GXR) reduces aggression and self injurious behavior in individuals with Prader Willi Syndrome (PWS). In addition, the study will establish the safety of GXR with a specific focus on metabolic effects.

Details

Lead sponsor	Maimonides Medical Center
Phase	PHASE4
Status	COMPLETED
Enrolment	15
Start date	Thu Dec 17 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Sat Dec 16 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Prader-Willi Syndrome
• Aggression
• Self-Injurious Behavior
• Pathologic Processes
• Behavioral Symptoms
• Intellectual Disability
• Neurobehavioral Manifestations
• Neurologic Manifestations
• Nervous System Diseases
• Abnormalities, Multiple

Interventions

• Guanfacine Extended Release
• Placebo

Countries

United States